Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Romiplostim · Nplate, AMG 531

Recombinant protein · Agonist of thrombopoietin receptor (THPO) · developed by Amgen

Approved FDA, Aug 2008
AMGN Developer
1 Registered trials

What is Romiplostim?

Romiplostim (Nplate) is a recombinant thrombopoietin receptor agonist that increases platelet production by binding and activating the TPO receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Nplate, AMG 531
Drug type
Recombinant protein
Targets
thrombopoietin receptor (THPO)
Mechanism
Agonist of thrombopoietin receptor (THPO)
Pathways
platelet production
Therapy area
Hematology
Developer
Amgen (AMGN)
FDA status
Approved as Nplate (August 22, 2008), BLA125268 · FDA label
UNII
GN5XU2DXKV

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07700238 Phase 3 Primary Immune Thrombocytopenia Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Immune Thrombocytopenia

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved ABP 692 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Romiplostim

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.